Search research articles
Contact Us
Filters
Showing results (61-70 of 139) with videos related to
Page
of 14
Sort By:
European Journal of Medicinal Chemistry
|
January 22, 2014
Benzofuran derivatives as a novel class of inhibitors of mTOR signaling
Christophe Salomé, Vanessa Narbonne, Nigel Ribeiro, et al.
Head & Neck
|
March 8, 2013
Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma
Sébastien Albert, Maria Eugenia Riveiro, Caroline Halimi, et al.
European Journal of Medicinal Chemistry
|
May 20, 2014
Benzofuran derivatives as anticancer inhibitors of mTOR signaling
Christophe Salomé, Nigel Ribeiro, Thierry Chavagnan, et al.
Cancer Investigation
|
October 18, 2019
Astonishing Evolution in Oropharyngeal Cancer with Immunotherapy: A Case Report
Alexandre Rossillon, Jonathan Benhamou, Laurent S Baccar, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
March 29, 2002
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion
Quang-Dé Nguyen, Sandrine Faivre, Erik Bruyneel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 1, 2008
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies
Sandrine Faivre, Catherine Delbaldo, Valérie Boige, et al.
Investigational New Drugs
|
June 10, 2006
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies
Hervé Ghesquières, Sandrine Faivre, Latifa Djafari, et al.
Targeted Oncology
|
May 16, 2012
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib
Sandrine Faivre, Maxime Ronot, Chantal Dreyer, et al.
Cancer Chemotherapy and Pharmacology
|
March 13, 2013
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
Maria Serova, Armand de Gramont, Annemilaï Tijeras-Raballand, et al.
Investigational New Drugs
|
April 22, 2014
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
Anna Patrikidou, Isabelle Sinapi, Hélène Regnault, et al.
Page
of 14
Search research articles
Search
Showing results (61-70 of 139) with videos related to
Sort By:
Page
of 14
European Journal of Medicinal Chemistry
|
January 22, 2014
Benzofuran derivatives as a novel class of inhibitors of mTOR signaling
Christophe Salomé, Vanessa Narbonne, Nigel Ribeiro, et al.
Head & Neck
|
March 8, 2013
Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma
Sébastien Albert, Maria Eugenia Riveiro, Caroline Halimi, et al.
European Journal of Medicinal Chemistry
|
May 20, 2014
Benzofuran derivatives as anticancer inhibitors of mTOR signaling
Christophe Salomé, Nigel Ribeiro, Thierry Chavagnan, et al.
Cancer Investigation
|
October 18, 2019
Astonishing Evolution in Oropharyngeal Cancer with Immunotherapy: A Case Report
Alexandre Rossillon, Jonathan Benhamou, Laurent S Baccar, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|
March 29, 2002
RhoA- and RhoD-dependent regulatory switch of Galpha subunit signaling by PAR-1 receptors in cellular invasion
Quang-Dé Nguyen, Sandrine Faivre, Erik Bruyneel, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 1, 2008
Safety of repeated administrations of ixabepilone given as a 3-hour infusion every other week in combination with irinotecan in patients with advanced malignancies
Sandrine Faivre, Catherine Delbaldo, Valérie Boige, et al.
Investigational New Drugs
|
June 10, 2006
Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies
Hervé Ghesquières, Sandrine Faivre, Latifa Djafari, et al.
Targeted Oncology
|
May 16, 2012
Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib
Sandrine Faivre, Maxime Ronot, Chantal Dreyer, et al.
Cancer Chemotherapy and Pharmacology
|
March 13, 2013
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib
Maria Serova, Armand de Gramont, Annemilaï Tijeras-Raballand, et al.
Investigational New Drugs
|
April 22, 2014
Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies
Anna Patrikidou, Isabelle Sinapi, Hélène Regnault, et al.
Page
of 14